Teva Pharma (TEVA) Tops Q3 EPS by 2c; Offers Q4 Outlook

November 15, 2016 7:01 AM EST
Get Alerts TEVA Hot Sheet
Trade TEVA Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

(Updated - November 15, 2016 7:05 AM EST)

Teva Pharma (NYSE: TEVA) reported Q3 EPS of $1.31, $0.02 better than the analyst estimate of $1.29. Revenue for the quarter came in at $5.56 billion versus the consensus estimate of $5.75 billion.

The company sees Q3 EPS of $1.34 - $1.44 with revenue of $6.2 - $6.5 billion. The Street sees EPS of $1.42 and revenue of $6.48 billion.

Teva also sees FY16 revenue of $21.6 - $21.9 billion and EPS of $5.10 - $5.20. Consensus estimates call for revenue of $22.1 billion and EPS of $5.16.

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Earnings, Guidance, Hot Earnings

Related Entities


Add Your Comment